S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Copper More Critical than Lithium? (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Copper More Critical than Lithium? (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Copper More Critical than Lithium? (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Copper More Critical than Lithium? (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
NASDAQ:ALLO

Allogene Therapeutics - ALLO Stock Forecast, Price & News

$15.03
-0.93 (-5.83%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$14.88
$16.04
50-Day Range
$7.70
$15.96
52-Week Range
$6.43
$27.86
Volume
1.84 million shs
Average Volume
1.87 million shs
Market Capitalization
$2.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.17

Allogene Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
87.4% Upside
$28.17 Price Target
Short Interest
Bearish
28.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of Allogene Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$271,880 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.59) to ($2.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

785th out of 1,098 stocks

Biological Products, Except Diagnostic Industry

125th out of 174 stocks

ALLO stock logo

About Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. JMP Securities reiterated a "buy" rating and issued a $23.00 price objective on shares of Allogene Therapeutics in a research note on Monday, April 11th. Raymond James reduced their price objective on shares of Allogene Therapeutics from $36.00 to $13.00 in a research note on Thursday, May 5th. Robert W. Baird assumed coverage on shares of Allogene Therapeutics in a research note on Thursday, June 2nd. They issued a "neutral" rating and a $11.00 price objective for the company. Finally, The Goldman Sachs Group upgraded shares of Allogene Therapeutics from a "neutral" rating to a "buy" rating and raised their price objective for the company from $9.00 to $32.00 in a research note on Friday, July 15th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $28.17.

Allogene Therapeutics Trading Down 5.8 %

Shares of NASDAQ:ALLO traded down $0.93 during midday trading on Tuesday, reaching $15.03. 1,843,185 shares of the stock were exchanged, compared to its average volume of 1,869,377. The company has a market capitalization of $2.16 billion, a P/E ratio of -7.25 and a beta of 0.55. Allogene Therapeutics has a 52-week low of $6.43 and a 52-week high of $27.86. The stock has a 50 day moving average price of $11.65 and a 200-day moving average price of $9.94.

Insider Transactions at Allogene Therapeutics

In other news, Director Owen N. Witte sold 10,000 shares of Allogene Therapeutics stock in a transaction dated Wednesday, June 22nd. The shares were sold at an average price of $11.76, for a total transaction of $117,600.00. Following the completion of the sale, the director now directly owns 233,271 shares in the company, valued at $2,743,266.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Owen N. Witte sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 22nd. The shares were sold at an average price of $11.76, for a total value of $117,600.00. Following the sale, the director now directly owns 233,271 shares of the company's stock, valued at $2,743,266.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Rafael Amado sold 11,500 shares of the firm's stock in a transaction that occurred on Thursday, May 19th. The stock was sold at an average price of $7.40, for a total transaction of $85,100.00. Following the completion of the sale, the chief marketing officer now directly owns 546,257 shares in the company, valued at $4,042,301.80. The disclosure for this sale can be found here. Insiders sold a total of 27,500 shares of company stock worth $271,880 over the last ninety days. 26.30% of the stock is currently owned by corporate insiders.

Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLO Stock News Headlines

What 4 Analyst Ratings Have To Say About Allogene Therapeutics
Allogene Therapeutics Q1 2022 Earnings Preview
Allogene Flat on Study Results
See More Headlines
Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLO Company Calendar

Last Earnings
11/04/2021
Today
8/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALLO
Fax
N/A
Employees
308
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.17
High Stock Price Forecast
$43.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+87.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
14 Analysts

Profitability

Net Income
$-257,010,000.00
Net Margins
-148,214.64%
Pretax Margin
-148,214.66%

Debt

Sales & Book Value

Annual Sales
$38.49 million
Book Value
$6.43 per share

Miscellaneous

Free Float
105,833,000
Market Cap
$2.16 billion
Optionable
Not Optionable
Beta
0.55

Key Executives














ALLO Stock - Frequently Asked Questions

Should I buy or sell Allogene Therapeutics stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALLO shares.
View ALLO analyst ratings
or view top-rated stocks.

What is Allogene Therapeutics' stock price forecast for 2022?

14 analysts have issued 1 year price targets for Allogene Therapeutics' shares. Their ALLO share price forecasts range from $11.00 to $43.00. On average, they predict the company's share price to reach $28.17 in the next year. This suggests a possible upside of 87.4% from the stock's current price.
View analysts price targets for ALLO
or view top-rated stocks among Wall Street analysts.

How has Allogene Therapeutics' stock price performed in 2022?

Allogene Therapeutics' stock was trading at $14.92 on January 1st, 2022. Since then, ALLO shares have increased by 0.7% and is now trading at $15.03.
View the best growth stocks for 2022 here
.

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced its earnings results on Thursday, November, 4th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by $0.01. The company had revenue of $0.05 million for the quarter. Allogene Therapeutics had a negative net margin of 148,214.64% and a negative trailing twelve-month return on equity of 32.28%. During the same period in the previous year, the firm earned ($0.52) EPS.

What is David Chang's approval rating as Allogene Therapeutics' CEO?

2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an IPO on Thursday, October 11th 2018. The company issued 16,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO.

What is Allogene Therapeutics' stock symbol?

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Mirae Asset Global Investments Co. Ltd. (0.23%), Gratus Capital LLC (0.15%), Swiss National Bank (0.14%), Mitsubishi UFJ Kokusai Asset Management Co. Ltd. (0.12%), TD Asset Management Inc. (0.09%) and Vontobel Holding Ltd. (0.08%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Owen N Witte, Rafael Amado and Veer Bhavnagri.
View institutional ownership trends
.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allogene Therapeutics' stock price today?

One share of ALLO stock can currently be purchased for approximately $15.03.

How much money does Allogene Therapeutics make?

Allogene Therapeutics (NASDAQ:ALLO) has a market capitalization of $2.16 billion and generates $38.49 million in revenue each year. The company earns $-257,010,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis.

How many employees does Allogene Therapeutics have?

Allogene Therapeutics employs 308 workers across the globe.

How can I contact Allogene Therapeutics?

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.allogene.com. The company can be reached via phone at (650) 457-2700 or via email at ir@allogene.com.

This page (NASDAQ:ALLO) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.